Comparative Pharmacology
Head-to-head clinical analysis: GENOTROPIN versus ZOMACTON.
Peer-Reviewed Evidence
Head-to-head clinical analysis: GENOTROPIN versus ZOMACTON.
GENOTROPIN vs ZOMACTON
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Recombinant human growth hormone (somatropin) binds to growth hormone receptors, activating JAK2/STAT5 signaling pathway, stimulating IGF-1 production and promoting linear growth, protein synthesis, and lipolysis.
ZOMACTON is a recombinant human growth hormone that binds to growth hormone receptors on cell surfaces, activating intracellular signaling cascades (primarily JAK-STAT pathway) leading to increased IGF-1 production, which mediates growth and metabolic effects including linear growth, protein synthesis, and lipolysis.
0.2 mg (0.6 IU) subcutaneously once daily; titrate based on clinical response and IGF-1 levels. Maximum dose: 0.8 mg (2.4 IU) daily.
Intramuscular or subcutaneous injection: 0.1-0.3 mg/kg/day (up to 0.6 mg/kg/day) divided into 1-2 doses. Typical adult dose for growth hormone deficiency: 0.2 mg/kg/day subcutaneously.
None Documented
None Documented
Subcutaneous: 3.9 hours (range 2.3–6.1 hours). Clinical context: supports daily dosing; residual GH activity may extend due to reversible binding to GHBP.
Terminal elimination half-life: 2-3 hours after subcutaneous administration; clinically, this necessitates daily or more frequent dosing.
Renal (glomerular filtration and tubular reabsorption); approximately 70% of the administered dose is recovered in urine, primarily as intact hormone.
Renal: nearly 100% of absorbed dose, mostly as intact hormone; negligible biliary/fecal elimination.
Category C
Category C
Growth Hormone
Growth Hormone